McDonagh TA et al (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 24(1):4–131

Google Scholar 

National Collaborating Centre for Chronic Conditions (Great Britain) (2003) Chronic Heart Failure: national clinical guideline for diagnosis and management in primary and secondary care. Royal College Phys

Tomasoni D et al (2020) Heart failure in the last year: progress and perspective. ESC Heart Failure 7(6):3505–3530

Article  PubMed  PubMed Central  Google Scholar 

Lin AH et al (2017) Repeat hospitalizations predict mortality in patients with heart failure. Mil Med 182(9–10):e1932–e1937

Article  PubMed  Google Scholar 

Armstrong PW et al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382(20):1883–1893

Article  CAS  PubMed  Google Scholar 

Butler J et al (2020) Clinical and economic burden of chronic heart failure and reduced ejection fraction following a worsening heart failure event. Adv Ther 37:4015–4032

Article  PubMed  PubMed Central  Google Scholar 

Bui A, Horwich T, Fonarow G (2011) Epidemiology and risk profile of heart failure. Nature Rev Cardiol 8(1):30–41. Epub 2010/11/10. https://doi.org/10.1038/nrcardio.2010.165. PMID: 21060326

Lesyuk W, Kriza C, Kolominsky-Rabas P (2018) Cost-of-illness studies in heart failure: a systematic review 2004–2016. BMC Cardiovasc Disord 18(1):1–11

Article  Google Scholar 

Tumanan-Mendoza BA et al (2018) Economic burden of hospitalisation for congestive heart failure among adults in the Philippines. Heart Asia 10(2)

Kristin E et al (2022) Budget impact analysis of Sacubitril Valsartan in the Treatment of heart failure and reduced ejection fraction (HFrEF) in Indonesia setting. Indo J Pharm 83–92

Zhang Y et al (2023) Current status and challenges in prenatal and neonatal screening, diagnosis, and management of congenital heart disease in China. The Lancet Child Adolesc Health

Cariou C et al (2017) Budget impact analysis of sacubitril/valsartan introduction for heart failure treatment from the French hospital perspective. Value in Health 20(9):A607

Article  Google Scholar 

Ponikowski P et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiologia Polska (Polish Heart Journal) 74(10):1037–1147

Article  PubMed  Google Scholar 

Piperidou A, Loutradis C, Sarafidis P (2021) SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. J Hum Hypertens 35(1):12–25

Article  PubMed  Google Scholar 

Lin X et al (2022) Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective. J Thorac Dis 14(5):1588

Article  PubMed  PubMed Central  Google Scholar 

Sul J et al (2016) FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 21(5):643–650

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trueman P, Drummond M, Hutton J (2001) Developing guidance for budget impact analysis. Pharmacoeconomics 19:609–621

Article  CAS  PubMed  Google Scholar 

Mauskopf J et al (2017) Introduction to budget-impact analysis. Budget-Impact Analysis of Health Care Interventions: A Practical Guide 1–10

Garattini L, van de Vooren K (2011) Budget impact analysis in economic evaluation: a proposal for a clearer definition. Eur J Health Econ 12(6):499–502

Article  PubMed  Google Scholar 

Sullivan SD et al (2014) Budget impact analysis—principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value in health 17(1):5–14

Article  PubMed  Google Scholar 

Silva MT, Silva END, Pereira MG (2017) Budget impact analysis. Epidemiologia e Serviços de Saúde 26:421–424

Article  PubMed  Google Scholar 

Mauskopf JA et al (2007) Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices—budget impact analysis. Value in health 10(5):336–347

Article  PubMed  Google Scholar 

Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 88:105906

Article  PubMed  Google Scholar 

Alsumali A et al (2021) Budget impact analysis of vericiguat for the treatment of chronic heart failure with reduced ejection fraction following a worsening event. Adv Ther 38:2631–2643

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bisognano J et al (2021) Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States. BMC Cardiovasc Disord 21:1–9

Article  Google Scholar 

Gaziano TA et al (2020) Cost-effectiveness of sacubitril-valsartan in hospitalized patients who have heart failure with reduced ejection fraction. JAMA cardiology 5(11):1236–1244

Article  PubMed  PubMed Central  Google Scholar 

Borer JS et al (2016) Budget impact of adding ivabradine to standard of care in patients with chronic systolic heart failure in the United States. J Manag Care Spec Pharm 22(9):1064–1071

PubMed  Google Scholar 

Smith DG, Cerulli A, Frech FH (2005) Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis. Clin Ther 27(6):951–959

Article  PubMed  Google Scholar 

Smith DG et al (2007) Estimated cost savings associated with the use of valsartan in heart failure in a large US health plan. J Med Econ 10(3):229–238

Article  Google Scholar 

Chiong JR et al (2012) Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. J Med Econ 15(2):276–284

Article  PubMed  Google Scholar 

McEwan P et al (2023) Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation. Eur J Heart Fail 25(3):389–398

Article  PubMed  Google Scholar 

Gandjour A, Ostwald DA (2018) Sacubitril/valsartan (LCZ696): a novel treatment for heart failure and its estimated cost effectiveness, budget impact, and disease burden reduction in Germany. Pharmacoeconomics 36:1285–1296

Article  PubMed  Google Scholar 

Theidel U et al (2017) Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. ESC heart failure 4(3):274–281

Article  PubMed  PubMed Central  Google Scholar 

Bourguignon S et al (2019) Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France. ESC heart failure 6(3):559–569

Article  PubMed  PubMed Central  Google Scholar 

Delgado JF et al (2020) Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain. J Med Econ 23(12):1418–1424

Article  PubMed  Google Scholar 

Leong RN et al (2023) Budget impact analysis of utilization of Sacubitril/Valsartan for the treatment of heart failure with reduced ejection fraction in the Philippines. Value in Health Regional Issues 36:105–116

Article  PubMed  Google Scholar 

Ratanasumawong K, Piyayotai D, Makarawate P (2022) POSC106 budget impact analysis of including Sacubitril/Valsartan in the national formulary for the treatment of Heart Failure with Reduced Ejection Fraction (HFREF) in Thailand. Value in Health 25(1):S107

Article  Google Scholar 

Brock E et al (2014) Budget impact of parenteral iron treatment of iron deficiency: methodological issues raised by using real-life data. Eur J Health Econ 15:907–916

Article  PubMed  Google Scholar 

Wong B et al (2021) Study of patients with iron deficiency and HF in Ireland: prevalence and treatment budget impact. The British J Cardiol 28(1)

Rognoni C, Gerzeli S (2019) Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost–effectiveness and budget impact. Journal of comparative effectiveness research 8(11):1099–1110

Article  PubMed  Google Scholar 

Lorenzovici L et al (2019) Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Romania. Journal of Cardiovascular Emergencies 5(4):131–139

Article  Google Scholar 

Niezen MG et al (2009) Finding legitimacy for the role of budget impact in drug reimbursement decisions. Int J Technol Assess Health Care 25(1):49–55

Article  PubMed  Google Scholar 

Pearson SD (2018) The ICER value framework: integrating cost effectiveness and affordability in the assessment of health care value. Value in health 21(3):258–265

Article  MathSciNet  PubMed  Google Scholar 

McCabe N et al (2017) Six-minute walk distance predicts 30-day readmission after acute heart failure hospitalization. Heart Lung 46(4):287–292

Article  PubMed  Google Scholar 

Borisenko O et al (2018) An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany. BMC Cardiovasc Disord 18:1–10

Article  Google Scholar 

Nakao Y et al (2022) Cost-effectiveness of long-term tolvaptan administration for chronic heart failure treatment in Japan. J Cardiol 79(3):408–416

Article  PubMed  Google Scholar 

Dasta JF et al (2018) Economic impact of tolvaptan treatment vs. fluid restriction based on real-world data among hospitalized patients with heart failure and hyponatremia. Hosp Pract 46(4):197–202

Article  Google Scholar 

Swedberg K et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet 376(9744):875–885